Key result
Annual structured assessment identifies undiagnosed diabetes in ~2% of IHD and hypertensive patients.
Why the study?
Does an annual structured assessment identify undiagnosed diabetes and IGT/IFG in patients with hypertension or ischaemic heart disease?
Cross-Sectional
Does an annual structured assessment identify undiagnosed diabetes and IGT/IFG in patients with hypertension or ischaemic heart disease?
Screening for undiagnosed diabetes and impaired glucose tolerance in primary care patients with hypertension or ischemic heart disease yields a clinically relevant number of new diagnoses.
Diabetes mellitus causes significant morbidity and mortality, and up to 50% of people with diabetes may be as yet undiagnosed. Additionally impaired glucose tolerance (IGT) is known to increase vascular risk and the risk of developing diabetes. The aim of this study was to look for IGT and/or impaired fasting glucose (IFG) and undiagnosed diabetes amongst patients with hypertension and patients with ischaemic heart disease (IHD) as part of an annual structured assessment. In IHD patients the uptake was 83.45% with a yield of 2.47% for undiagnosed diabetes and 12.39% for IGT/IFG. In hypertensive patients the uptake was 75.84% with a yield of 2.01% for undiagnosed diabetes and 18.54% for IGT/IFG. We concluded that looking for undiagnosed type 2 diabetes and patients with IGT/IFG in primary care may be worthwhile amongst patients with hypertension or IHD.
No takes yet. Share an insight, caveat, or question.
Savage et al. (2003) conducted a cross-sectional in Hypertension and ischaemic heart disease. Annual structured assessment for diabetes screening was evaluated on Yield of undiagnosed diabetes and IGT/IFG. An annual structured assessment for diabetes screening identified undiagnosed diabetes in 2.47% of IHD patients and 2.01% of hypertensive patients, and IGT/IFG in 12.39% and 18.54% respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: